← Search & browse all drugs
DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR SYSTEMIC USE › Antifungals for systemic use
fosravuconazole
D01BA03
Forms & Strengths
- Oral capsules: 3.5 mg
- Oral capsules: 50 mg
Adult Dosing
- Onychomycosis: 35 mg once weekly for 12 weeks
- Tinea pedis: Dose varies by regional regulatory approval
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Treatment of onychomycosis caused by susceptible dermatophytes
- Treatment of tinea pedis
Mechanism of Action
- Triazole antifungal agent that inhibits fungal cytochrome P450-dependent 14alpha-demethylase
- Blocks ergosterol synthesis, leading to fungal cell membrane disruption and cell death
Contraindications
- Hypersensitivity to fosravuconazole, ravuconazole, or other azole antifungals
- Co-administration with strong CYP3A4 inducers
- Severe hepatic impairment
Adverse Reactions
- Nasopharyngitis
- Headache
- Diarrhea
- Elevated alanine aminotransferase (ALT)
- Elevated aspartate aminotransferase (AST)
Drug Interactions
- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) significantly decrease fosravuconazole exposure
- Inhibitors or substrates of specific CYP enzymes may have altered plasma concentrations
- Potential for QT prolongation when co-administered with other QT-prolonging drugs
Curated Content: Needs Vetting Before Put to Clinical Use